UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/813,965	03/31/2004	Robert Falotico	CRD-5073 NP	7706
27777 DIJI ID S. JOH	7590 08/24/2007	EXAMINER		
PHILIP S. JOH JOHNSON & J	OHNSON	KIM, JENNIFER M		
ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK, NJ 08933-7003			ART UNIT	PAPER NUMBER
			1617	
			C VALUE DATE	DEL WERV MODE
			MAIL DATE	DELIVERY MODE
			08/24/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)	Applicant(s)		
10/813,965	FALOTICO ET AL.	FALOTICO ET AL.		
Examiner	Art Unit			
Jennifer Kim	1617			

	Jennifer Kim	1617					
The MAILING DATE of this communication appe	ars on the cover sheet with	the correspondence add	lress				
THE REPLY FILED 16 August 2007 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE.							
1. The reply was filed after a final rejection, but prior to or on the same day as filing a Notice of Appeal. To avoid abandonment of this application, applicant must timely file one of the following replies: (1) an amendment, affidavit, or other evidence, which places the application in condition for allowance; (2) a Notice of Appeal (with appeal fee) in compliance with 37 CFR 41.31; or (3) a Request for Continued Examination (RCE) in compliance with 37 CFR 1.114. The reply must be filed within one of the following time periods:							
a) The period for reply expires 3_months from the mailing date b) The period for reply expires on: (1) the mailing date of this A no event, however, will the statutory period for reply expire to Examiner Note: If box 1 is checked, check either box (a) or (TWO MONTHS OF THE FINAL REJECTION. See MPEP 70	dvisory Action, or (2) the date so ater than SIX MONTHS from the b). ONLY CHECK BOX (b) WH	mailing date of the final reject	on.				
Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). NOTICE OF APPEAL							
2. The Notice of Appeal was filed on A brief in compliance with 37 CFR 41.37 must be filed within two months of the date of filing the Notice of Appeal (37 CFR 41.37(a)), or any extension thereof (37 CFR 41.37(e)), to avoid dismissal of the appeal. Since a Notice of Appeal has been filed, any reply must be filed within the time period set forth in 37 CFR 41.37(a). AMENDMENTS							
3. The proposed amendment(s) filed after a final rejection, last the proposed amendment(s) filed after a final rejection, last the issues that would require further control to the proposed amendment(s) filed after a final rejection, last the issue of new matter (see NOTE below the issue of new matter (see NOTE below the issue of new matter).	3. The proposed amendment(s) filed after a final rejection, but prior to the date of filing a brief, will <u>not</u> be entered because (a) They raise new issues that would require further consideration and/or search (see NOTE below);						
(c) They are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or							
(d) They present additional claims without canceling a NOTE: See Continuation Sheet. (See 37 CFR 1.1	· -	ally rejected claims.					
4. The amendments are not in compliance with 37 CFR 1.12	* **	lon-Compliant Amendment	(PTOL-324)				
5. Applicant's reply has overcome the following rejection(s)		·	(1 TOL-024).				
 Newly proposed or amended claim(s) would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s). 							
7. For purposes of appeal, the proposed amendment(s): a) will not be entered, or b) will be entered and an explanation of how the new or amended claims would be rejected is provided below or appended. The status of the claim(s) is (or will be) as follows: Claim(s) allowed:							
Claim(s) objected to: Claim(s) rejected: <u>1,3-5 and 7</u> . Claim(s) withdrawn from consideration: <u>9 and 10</u> .							
AFFIDAVIT OR OTHER EVIDENCE							
8. The affidavit or other evidence filed after a final action, but before or on the date of filing a Notice of Appeal will <u>not</u> be entered because applicant failed to provide a showing of good and sufficient reasons why the affidavit or other evidence is necessary and was not earlier presented. See 37 CFR 1.116(e).							
9. The affidavit or other evidence filed after the date of filing a Notice of Appeal, but prior to the date of filing a brief, will <u>not</u> be entered because the affidavit or other evidence failed to overcome <u>all</u> rejections under appeal and/or appellant fails to provide a showing a good and sufficient reasons why it is necessary and was not earlier presented. See 37 CFR 41.33(d)(1).							
10. The affidavit or other evidence is entered. An explanation of the status of the claims after entry is below or attached. REQUEST FOR RECONSIDERATION/OTHER							
11. The request for reconsideration has been considered but does NOT place the application in condition for allowance because:							
12. Note the attached Information Disclosure Statement(s). (PTO/SB/08) Paper No(s) 13. Other:							
	•						
	•	Jennifer Kim Patent Examiner Art Unit 1617					

Continuation Sheet (PTO-303)

Application No. 10/813,965

Continuation of 3. NOTE: The proposed amendment comprising the specific range of rapamycin requires further search. Thus, the proposed amendments will not be entered and the claims fail to patentably distinguish over the state of the art as represented by obvious composition of the cited references..